Black Diamond Therapeutics
IPODefeating Cancer Resistance
Public · Cambridge, United States · Founded 2017 · $170.0M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- blackdiamondtherapeutics.com
- Total Funding
- $170.0M
- Last Round
- $85.0M Series CDec 2019
- Rounds
- 2
- Type
- Public
About
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target broad families of oncogenic mutations in clinically validated targets. The company's lead programs focus on non-small cell lung cancer (NSCLC) and glioblastoma (GBM), with silevertinib as its clinical-stage brain-penetrant EGFR inhibitor. Black Diamond trades on Nasdaq under the ticker BDTX.
Summary
Black Diamond Therapeutics is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $170.0M in total across 2 rounds, most recently a $85.0M Series C round in Dec 2019. Investors include Boxer Capital, New Enterprise Associates and RA Capital Management.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2023
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company